Partnering with Kantify at BIO-Europe 2025: AI for Drug Discovery

Kantify will be attending BIO-Europe 2025 in Vienna, Austria, from November 3–5 (with digital partnering on November 11–12).

We invite biopharma executives to connect with us to discuss accelerating your drug pipelines using our proprietary Artificial Intelligence platform, Sapian.

---

Driving Efficiency with Sapian AI

Drug discovery today demands an accelerated and de-risked approach. Our platform, Sapian, delivers this by integrating advanced AI capabilities into the entire early-stage process, focusing on challenging and unmet medical needs, particularly within oncology and rare diseases.

We are scheduling meetings with potential partners interested in:

• AI-Powered Target Identification: Partnering to validate and prosecute novel, disease-driving targets.
• Hit-to-Lead Optimization: Leveraging Sapian to screen and prioritize up to 10 Billion molecules per day to quickly generate high-confidence small molecule candidates.
• Co-Development and Licensing: Opportunities to advance our validated preclinical assets, including a promising breakthrough in a rare cancer (liposarcoma), toward the clinic.

---

Request a Meeting via partneringONE

Our team is ready to demonstrate how the radically innovative intelligence of Sapian AI can be deployed to reduce time, cost, and risk in small molecule discovery programs.

Kantify at BIO-Europe 2025
In-Person: November 3–5, Vienna Congress and Convention Center
Digital: November 11–12

We look forward to productive discussions that drive innovation in medicine.